Rapport Therapeutics, Inc. (RAPP)
Health Care ยท Pharmaceutical Preparations
Rapport Therapeutics, Inc. (RAPP) is listed on Nasdaq, where its shares have traded since June 7, 2024. SentiSense covers Rapport Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Abraham N. Ceesay is its chief executive officer. The company reports 84 employees, and its corporate website is www.rapportrx.com.
About Rapport Therapeutics, Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 152 institutions reported holding RAPP, with 51.3 million shares worth $2.1 billion in aggregate. The largest reported holders were FMR, Trv GP V and Arch Venture Management. Of the 5 largest reported holders, 1 added shares, 3 reduced their positions and 1 held its position unchanged during the quarter.
More on RAPP
- RAPP sentiment: whether news and social coverage of Rapport Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- RAPP ownership: all 152 reporting institutions, plus insider and congressional trades.
- RAPP financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Rapport Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Rapport Therapeutics, Inc. do?
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders.
What sector is RAPP in?
SentiSense classifies Rapport Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does RAPP stock trade?
Rapport Therapeutics, Inc. (RAPP) is listed on Nasdaq, where its shares have traded since June 7, 2024.
Who is the CEO of Rapport Therapeutics, Inc.?
Abraham N. Ceesay is the chief executive officer of Rapport Therapeutics, Inc..